Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Cabaletta Bio
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
July 02, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
June 14, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
May 29, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
May 15, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 13, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 21, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
March 20, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
February 27, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
February 01, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
January 08, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
November 28, 2023
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
November 06, 2023
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November
October 30, 2023
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201
October 02, 2023
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
September 19, 2023
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September
August 30, 2023
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201
August 22, 2023
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors
July 24, 2023
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio to Present at the Jefferies Healthcare Conference
May 31, 2023
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares
May 22, 2023
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Announces Pricing of Public Offering of Common Stock
May 17, 2023
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Announces Proposed Public Offering of Common Stock
May 17, 2023
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis
May 16, 2023
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting
May 02, 2023
From
Cabaletta Bio
Via
GlobeNewswire
Tickers
CABA
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.